Drug Detail

Information about Komzifti

Generic Name	Ziftomenib
IND	KO-539
Brand Name (US)	Komzifti
Manufacturer	Kura Oncology Inc
Drug Type	Disrupts transcription/chromatin regulators(DOT1L)
Delivery	Oral
Approval Status	Approved for a non-GIST cancer
Indications	AML GIST
Overall Strategy	Synthetic lethality via KIT when combined with a KIT inhibitor
Strategy	Reduce menin-MLL epigenetic upregulatiion of KIT transcription
Drug Category	Menin inhibitor

Possible mechanism of action. Imatinib causes vulnerability that can be targeted by ziftomenib at the transcriptional and/or protein stability levels, creating synthetic lethality.